2 Bounce Back Stocks Play: CEL-SCI Corporation (CVM ), Arrowhead Pharmaceuticals (ARWR)

CEL-SCI Corporation (NYSEAMERICAN:CVM) releases details from discussion of results of CEL-SCI’s Phase 3 trial at the Annual Shareholder Meeting on July 1

The discussion on the Phase 3 results was presented by Geert Kersten the Chief Executive Officer, Dr. Eyal Talor the Chief Scientific Officer and John Cipriano the Senior Vice President of Regulatory Affairs. In the landmark Phase 3 study, Multikine produced a significant 14.1% 5-year survival benefit (62.7% vs 48.6%) in the group of advanced primary head and neck cancer patients who received surgery plus radiotherapy. The Company plans to file for FDA approval in this patient population.

CVM stock is tanking hard and now down by 12.37% to $7.58. The stock is the biggest loser of the week with a slump of over 70%.

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares -27% after announcing voluntary pause of AROENaC1001 trial

AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference therapeutic being developed as a treatment for patients with cystic fibrosis, after receiving a preliminary update from an ongoing chronic toxicology study in rats that contained unexpected signals of local lung inflammation. The company has instructed investigators to pause new screening, enrollment, and any further dosing of investigational ARO-ENaC pending additional data from the ongoing chronic rat toxicology study and an additional ongoing chronic primate toxicology study.

At the time of writing, ARWR stock is trading lower by 27% to $61.59 on hefty volume.